MannKind Corporation - Common Stock (MNKD)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 11, 2026Investment Snapshot
- P/E of 209.5 — elevated valuation multiple
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 31.7% — good return on equity
- Revenue growing at 22% annually
MannKind Corporation - Common Stock (MNKD) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.1 billion . Key value metrics: P/E ratio 209.5, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
MannKind Corporation - Common Stock — Fundamental Analysis Summary
MannKind Corporation - Common Stock (MNKD) trades at a trailing P/E of 209.5x — 732% above the Healthcare sector average of 25.2x.
On financial health, MNKD shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 31.7% (sector average: -20.6%).
StockPik's composite Value Score for MNKD is 42/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MNKD reports a high gross margin of 93.8% (sector average: 40.1%) and a solid operating margin of 13.7%.
MNKD shows revenue growing at 22% year-over-year, with earnings declining at 79%.